References
- Alagozlu H, Ozdemir O, Koksal B, Yilmaz A, Coskun M (2013). Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Asian Pac J Cancer Prev, 14, 5489-94. https://doi.org/10.7314/APJCP.2013.14.9.5489
- Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999). Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer, 81, 69-74. https://doi.org/10.1038/sj.bjc.6690652
- Arcaini L, Merli M, Passamonti F, et al (2010). Impact of treatment related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol, 85, 46-50.
- Besson C, Canioni D, Lepage E, et al (2006). Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol, 24, 953-60. https://doi.org/10.1200/JCO.2005.01.5016
- Cainelli F, Longhi MS, Concia E, Vento S (2001). Failure of lamuvidine therapy for chemotherapy induced reactivation of hepatitis. Am J Gastroenterol, 96, 1651-2. https://doi.org/10.1111/j.1572-0241.2001.03824.x
- Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998). Successful treatment with lamuvidine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol, 9, 385-7. https://doi.org/10.1023/A:1008206519571
- Custer B, Sullivan SD, Hazlet TK, et al (2004). Global epidemiology of hepatitis B virus. J Clin Gastroenterol, 38, 158-68. https://doi.org/10.1097/00004836-200411003-00008
- European Association for the Study of the Liver (2011). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol, 55, 245-64. https://doi.org/10.1016/j.jhep.2011.02.023
- Gurol E, Saban C, Oral O, Cigdem A, Armagan A (2006). Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol, 21, 299-305. https://doi.org/10.1007/s10654-006-0001-2
- Hwang YY, Liang RH (2010). Hepatitis C in haematological patients. Hepat Res Treat, 2010, 961359.
- Kanamori H, Fukawa H, Maruta A, et al (1992). Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci, 303, 109-11. https://doi.org/10.1097/00000441-199202000-00009
- Kohrt HE, Ouyang DL, Keeffe EB (2006). Systematic review: lamuvidine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther, 24, 1003-16. https://doi.org/10.1111/j.1365-2036.2006.03081.x
- Kose S, Olmezoglu A, Gozaydin A, Ece G (2011). Seroprevalence of Hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr, 29, 652-5.
- Kumagai K, Takagi T, Nakamura S, et al (1997). Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol, 8, 107-9. https://doi.org/10.1023/A:1008234807768
- Lau GK, Yiu HH, Fong DY, et al (2003). Early is superior to deferred preemptive lamuvidine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterol, 125, 1742-9. https://doi.org/10.1053/j.gastro.2003.09.026
- Lavanchy D (2004). Hepatitis B virus epidemiology, disaese burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107. https://doi.org/10.1046/j.1365-2893.2003.00487.x
- Long M, Jia W, Li S, et al (2011). A single center, prospective and randomized controlled study: Can the prophylactic use of lamuvidine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat, 127, 705-12. https://doi.org/10.1007/s10549-011-1455-9
- Loomba R, Rowley A, Wesley R, et al (2008). Systematic review: the effect of preventive lamuvidine on Hepatitis B reactivation during chemotherapy. Ann Intern Med, 148, 519-28. https://doi.org/10.7326/0003-4819-148-7-200804010-00008
- Mehmet D, Meliksah E, Serif Y, et al (2005). Prevalence of hepatitis B infection in the southeast region of Turkey: comparison of risk factors in rural and urban areas. Jpn J Infect Dis, 58, 15-9.
- Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996). Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer, 78, 2210-5. https://doi.org/10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0
- Persico M, De Marino F, Russo GD, et al (2002). Efficacy of lamuvidine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood, 99, 724-5. https://doi.org/10.1182/blood.V99.2.724
- Soh LT, Ang PT, Sng I, Chua EJ, Ong YW (1992). Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer, 28, 1338-9. https://doi.org/10.1016/0959-8049(92)90513-2
- Steinberg JL, Yeo W, Zhong S, et al (2000). Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: procore/core mutations may play an important role. J Med Virol, 60, 249-55. https://doi.org/10.1002/(SICI)1096-9071(200003)60:3<249::AID-JMV1>3.0.CO;2-C
- Ter Borg F, Smorenburg S, de Man RA, et al (1998). Recovery from life threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamuvidine therapy. Dig Dis Sci, 43, 2267-70. https://doi.org/10.1023/A:1026622807373
- Utkan G, Azap A, Muallaoglu S, et al (2006). Hepatitis B and C in cancer patients: case-control study. Int J Hematol Oncol, 16, 103-7.
- Uzun K, Alici S, Ozbay B, Gencer M, Irmak H (2002). The incidence of hepatitis C virus in patients with lung cancer. Turkish Respiratory J, 3, 91-3.
- Vento S, Cainelli F, Mirandola F, et al (1996). Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347, 92-3. https://doi.org/10.1016/S0140-6736(96)90212-3
- Yazici Y, Demir N, Cinarka H, Yilmaz H, Altintas N (2010). Seroprevalences of HBV, HCV and HIV among healthcare workers of Trabzon Chest Diseases Hospital. Turkish Bull Hyg Experiment Biol, 67, 27-32.
- Yeo W, Chan PK, Zhong S, et al (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 62, 299-307. https://doi.org/10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
- Yeo W, Chan PK, Hui P, et al (2003). Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol, 70, 553-61. https://doi.org/10.1002/jmv.10430
- Yeo W, Ho WM, Hui P, et al (2004). Use of lamuvidine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat, 88, 209-15. https://doi.org/10.1007/s10549-004-0725-1
- Yeo W, Johnson PJ (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209-20. https://doi.org/10.1002/hep.21051
- Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM (1998). Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer, 83, 1224-30. https://doi.org/10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6
Cited by
- Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-2033-z
- The oncologic burden of hepatitis C virus infection: A clinical perspective vol.67, pp.5, 2017, https://doi.org/10.3322/caac.21403